Table 2. Clinicopathological characteristics of patients with and without KRAS mutations in postoperative serum.
|
KRAS
mutation status in postoperative serum |
|||
|---|---|---|---|
| Parameter | Negative (n=25) | Positive (n=20) | P |
| Age, years (median (range)) | 70 (38–80) | 70 (48–87) | 0.672 |
| Sex, n (%) | 0.403 | ||
| Male | 17 (68.0) | 12 (60.0) | |
| Female | 8 (32.0) | 8 (40.0) | |
| Diabetes mellitus, n (%) | 6 (24.0) | 8 (40.0) | 0.204 |
| Family cancer history, n (%) | 10 (40.0) | 7 (35.0) | 0.487 |
| Procedure, n (%) | 0.178 | ||
| Pancreaticoduodenectomy | 16 (64.0) | 9 (45.0) | |
| Distal pancreatectomy | 6 (24.0) | 10 (50.0) | |
| Total pancreatectomy | 3 (12.0) | 1 (5.0) | |
| NACRT, n (%) | 0.167 | ||
| Performed | 8 (32.0) | 3 (15.0) | |
| Resection status, n (%) | 0.352 | ||
| R0 | 21 (84.0) | 15 (75.0) | |
| R1 | 4 (16.0) | 5 (25.0) | |
| Lymph node metastasis, n (%) | 0.481 | ||
| N0 | 5 (20.0) | 5 (25.0) | |
| N1 | 20 (80.0) | 15 (75.0) | |
| Stage (UICC), n (%) | 0.260 | ||
| IA | 2 (8.0) | 0 (0.0) | |
| IB | 0 (0.0) | 0 (0.0) | |
| IIA | 3 (12.0) | 5 (25.0) | |
| IIB | 20 (80.0) | 15 (75.0) | |
| III | 0 (0.0) | 0 (0.0) | |
| IV | 0 (0.0) | 0 (0.0) | |
| Perioperative chemotherapy, n (%) | |||
| PI | 19 (76.0) | 13 (72.7) | 0.315 |
| Adjuvant chemotherapy, n (%) | |||
| S-1 or GEM | 20 (80.0) | 16 (72.7) | 0.642 |
| First recurrence region | |||
| Liver | 3 (12.0) | 4 (20.0) | 0.229 |
| Lung | 2 (8.0) | 4 (20.0) | 0.131 |
| Peritoneal | 1 (4.0) | 4 (20.0) | 0.126 |
| Local | 3 (12.0) | 2 (10.0) | 0.553 |
| Lymph node | 0 (0.0) | 0 (0.0) | |
Abbreviations: GEM=gemcitabine; NACRT=neo-adjuvant chemoradiotherapy; PI=portal infusion; UICC=Union for International Cancer Control.